Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 237

1.

New clinical perspectives of hypolipidemic drug therapy in severe hypercholesterolemia.

Stefanutti C, Morozzi C, Di Giacomo S.

Curr Med Chem. 2012;19(28):4861-8. Review.

PMID:
22963620
2.

New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.

Sahebkar A, Watts GF.

Clin Ther. 2013 Aug;35(8):1082-98. doi: 10.1016/j.clinthera.2013.06.019. Epub 2013 Aug 8. Review.

PMID:
23932550
3.

Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.

Urban D, Pöss J, Böhm M, Laufs U.

J Am Coll Cardiol. 2013 Oct 15;62(16):1401-8. doi: 10.1016/j.jacc.2013.07.056. Epub 2013 Aug 21. Review.

4.

Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.

Cziraky MJ, Watson KE, Talbert RL.

J Manag Care Pharm. 2008 Oct;14(8 Suppl):S3-28; quiz S30-1. Review.

PMID:
19891279
5.

Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol.

Della Badia LA, Elshourbagy NA, Mousa SA.

Pharmacol Ther. 2016 Aug;164:183-94. doi: 10.1016/j.pharmthera.2016.04.011. Epub 2016 Apr 29. Review.

PMID:
27133571
7.

2017 Taiwan lipid guidelines for high risk patients.

Li YH, Ueng KC, Jeng JS, Charng MJ, Lin TH, Chien KL, Wang CY, Chao TH, Liu PY, Su CH, Chien SC, Liou CW, Tang SC, Lee CC, Yu TY, Chen JW, Wu CC, Yeh HI; Writing Group of 2017 Taiwan Lipid Guidelines for High Risk Patients.

J Formos Med Assoc. 2017 Apr;116(4):217-248. doi: 10.1016/j.jfma.2016.11.013. Epub 2017 Feb 24. Review.

8.

Novel treatment options for the management of heterozygous familial hypercholesterolemia.

Polychronopoulos G, Tziomalos K.

Expert Rev Clin Pharmacol. 2017 Dec;10(12):1375-1381. doi: 10.1080/17512433.2017.1378096. Epub 2017 Sep 14. Review.

PMID:
28884604
9.

Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.

Evans M, Roberts A, Davies S, Rees A.

Drugs. 2004;64(11):1181-96. Review.

PMID:
15161326
10.
11.

Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition.

Tibolla G, Norata GD, Artali R, Meneghetti F, Catapano AL.

Nutr Metab Cardiovasc Dis. 2011 Nov;21(11):835-43. doi: 10.1016/j.numecd.2011.06.002. Epub 2011 Sep 23. Review.

PMID:
21943799
12.

What are we able to achieve today for our patients with homozygous familial hypercholesterolaemia, and what are the unmet needs?

Santos RD.

Atheroscler Suppl. 2014 Sep;15(2):19-25. doi: 10.1016/j.atherosclerosissup.2014.07.003. Review.

PMID:
25257073
13.

New therapies to reduce low-density lipoprotein cholesterol.

Wierzbicki AS, Viljoen A, Hardman TC, Mikhailidis DP.

Curr Opin Cardiol. 2013 Jul;28(4):452-7. doi: 10.1097/HCO.0b013e3283605fa2. Review.

PMID:
23736819
14.

Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.

Agabiti Rosei E, Salvetti M.

High Blood Press Cardiovasc Prev. 2016 Sep;23(3):217-30. doi: 10.1007/s40292-016-0155-2. Epub 2016 Aug 27. Review.

15.

Inhibition of PCSK9 as a novel strategy for the treatment of hypercholesterolemia.

Lopez D.

Drug News Perspect. 2008 Jul-Aug;21(6):323-30. doi: 10.1358/dnp.2008.21.6.1246795. Review.

PMID:
18836590
16.

Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia.

Bell DA, Hooper AJ, Watts GF, Burnett JR.

Vasc Health Risk Manag. 2012;8:651-9. doi: 10.2147/VHRM.S28581. Epub 2012 Nov 28. Review.

17.
18.

The next generation of novel low-density lipoprotein cholesterol-lowering agents: proprotein convertase subtilisin/kexin 9 inhibitors.

Shen L, Peng H, Xu D, Zhao S.

Pharmacol Res. 2013 Jul;73:27-34. doi: 10.1016/j.phrs.2013.04.001. Epub 2013 Apr 8. Review.

PMID:
23578522
19.

Promising new therapies for the treatment of hypercholesterolemia.

Valerio MG, Velayati A, Jain D, Aronow WS.

Expert Opin Biol Ther. 2016;16(5):609-18. doi: 10.1517/14712598.2016.1148136. Epub 2016 Feb 15. Review.

PMID:
26822080
20.

Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.

Reiner Z.

Nutr Metab Cardiovasc Dis. 2013 Sep;23(9):799-807. doi: 10.1016/j.numecd.2013.05.002. Epub 2013 Aug 9. Review.

PMID:
23932901

Supplemental Content

Support Center